Sanofi Sunrise Co. MyoKardia Sets Heart On Untapped Cardiomyopathy Market
Executive Summary
Emerging Company Profile: MyoKardia, a company backed by Sanofi's Sunrise initiative, has big development plans for the first therapeutic treatment targeting the root cause of hypertrophic cardiomyopathy – a chronic, progressive form of heart failure.
You may also be interested in...
MyoKardia Shares Skyrocket On Promising Phase II Data In HCM
Biotech hopes to accelerate clinical development plans for mavacamten after study meets several endpoints in obstructive hypertrophic cardiomyopathy, an unmet medical need.
Snapshot: April Highlights
A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series.
Transforming Patient Engagement At Novartis
Rising Leader Yolanda Tibbe, Novartis’s head of new commercial partnerships in Germany, talks about transformation at the Swiss big pharma and how to put ‘patients as customers’ thinking into action.